The interplay between IL-31, IL-33, eosinophils, and the tumor microenvironment (TME) could significantly influence immunotherapy outcomes in NSCLC, and understanding these mechanisms is crucial for enhancing therapeutic efficacy and overcoming treatment resistance. This evidence concerns the gene IL31 and non-small cell lung carcinoma.